Inflammatory biomarkers of ischemic stroke

Ischemic stroke remains the second leading cause of death and among the major causes of morbidity worldwide. Therapeutic options are currently limited to early reperfusion strategies, while pharmacological neuroprotective strategies despite showing promising results in the experimental setting constantly failed to enter the clinical arena. Inflammation plays an important role in the pathophysiology of ischemic stroke and mediators of inflammation have been longtime investigated as possible prognostic marker and therapeutic target for stroke patients. Here, we summarized available evidence on the role of cytokines, soluble adhesion molecules and adipokines in the pathophysiology, prognosis and therapy of ischemic stroke.

Automated summary

Ischemic stroke is the second leading cause of death globally and a major cause of morbidity. Current therapeutic options are limited to early reperfusion strategies, while pharmacological neuroprotective strategies have failed to enter clinical practice despite promising results in experiments. Inflammation plays a significant role in the pathophysiology of ischemic stroke, and inflammatory mediators have been investigated as potential prognostic markers and therapeutic targets. This article summarizes the available evidence on the role of cytokines, soluble adhesion molecules, and adipokines in the pathophysiology, prognosis, and therapy of ischemic stroke.